AAV Gene Therapy for MPS IVA with Induction of Immune Tolerance via Oral Administration of Epitope Peptides of N-Acetylgalactosamine-6-sulfate Sulfatase
International Journal of Molecular Sciences · 28.02.2026 · 27 (5) · 2278
DOI: 10.3390/ijms27052278 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 28.02.2026. Verfasst von Sampurna Saikia und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Research, Nemours Children's Health, Wilmington, DE 19803, USA. Hauptthemen laut MEDLINE: Mucopolysaccharidosis IV, Chondroitinsulfatases, Immune Tolerance, Genetic Therapy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, Austrian MPS Society, A Cure for Robert, Inc., The Morquio Community and Angelo Cali Family.
Abstract (Originalsprache)
Mucopolysaccharidosis IVA (MPS IVA) is caused by the accumulation of undegraded glycosaminoglycans due to the deficiency of the N-acetylgalactosamine-6-sulfate sulfatase (GALNS) enzyme. MPS IVA manifests as progressive systemic skeletal dysplasia. Gene therapy (GT) is potentially a one-time treatment in which the enzyme is continuously produced, circulated, and delivered to target tissues. However, immune responses to gene products can diminish therapeutic efficacy. We hypothesized that oral delivery of tolerogenic peptides induces immune tolerance to human GALNS (hGALNS) in MPS IVA mice, enhancing therapeutic efficacy. Neonatal mice deficient in mouse GALNS (mGALNS) were treated orally with three T-cell/B-cell epitope peptides or hGALNS protein on alternate days from day 3 after birth to day 20 before intravenous injection with AAV9 vectors encoding human GALNS on day 30. The results are encouraging, with anti-hGALNS antibodies undetectable in the plasma of orally administered peptide groups. hGALNS enzyme activities in plasma and tissues were higher in the orally treated groups than in the non-tolerized control group. Keratan sulfate levels in plasma, liver, and bone were normalized. Complete correction for heart vacuolization was achieved in peptide-treated groups, and partial correction for bone pathology was observed in all GT-treated groups. Overall, oral tolerance induction using immunodominant peptides promises to significantly enhance the efficacy of AAV-GT for MPS IVA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Research, Nemours Children's Health, Wilmington, DE 19803, USA.
- Department of Biological Sciences, University of Delaware, Newark, DE 19716, USA.
- Department of Pediatrics, Shimane University, Izumo 693-8501, Japan.
- Department of Pediatrics, Graduate School of Medicine, Gifu University, Gifu 501-1193, Japan.
- Department of Pediatrics, Thomas Jefferson University, Philadelphia, PA 19107, USA.
ORCID-Profile: Sampurna Saikia, Yasuhiko Ago, Fnu Nidhi, Zhengyu Ma, Shunji Tomatsu
Förderung
- NIH HHS
- Austrian MPS Society, A Cure for Robert, Inc.
- The Morquio Community and Angelo Cali Family
- The Bennett Foundation
- Fighting For Freya Foundation
- Scarlett Griffith Foundation
- Nemours Funds
- Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of Health
Zitieren
APA
Saikia, S., Ago, Y., Nidhi, F., Khan, S., Ma, Z., & Tomatsu, S. (2026). AAV Gene Therapy for MPS IVA with Induction of Immune Tolerance via Oral Administration of Epitope Peptides of N-Acetylgalactosamine-6-sulfate Sulfatase. International Journal of Molecular Sciences, 27(5), 2278. https://doi.org/10.3390/ijms27052278
Vancouver
Saikia S, Ago Y, Nidhi F, Khan S, Ma Z, Tomatsu S. AAV Gene Therapy for MPS IVA with Induction of Immune Tolerance via Oral Administration of Epitope Peptides of N-Acetylgalactosamine-6-sulfate Sulfatase. International Journal of Molecular Sciences. 2026;27(5):2278. doi:10.3390/ijms27052278
BibTeX
@article{Saikia2026,
author = {Saikia, Sampurna and Ago, Yasuhiko and Nidhi, Fnu and Khan, Shaukat and Ma, Zhengyu and Tomatsu, Shunji},
title = {AAV Gene Therapy for MPS IVA with Induction of Immune Tolerance via Oral Administration of Epitope Peptides of N-Acetylgalactosamine-6-sulfate Sulfatase},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {5},
pages = {2278},
doi = {10.3390/ijms27052278}
}
EUVIMED